Viewing data from:

XOLREMDI

NDA

MAVORIXAFOR | N218709 | X4 PHARMACEUTICALS INC

1 strength6 unique patents2 unique exclusivities

Patent Timeline

6 unique patents, 2 exclusivities by expiration date

Active (6)TodayExclusivity

2026

2027

2028

2029

2030

2031

2032

2033

2034

2035

2036

2037

2038

2039

Today

Dec. 11, 2038

Dec. 22, 2036

Dec. 14, 2036

Dec. 11, 2038

Dec. 22, 2036

Dec. 11, 2038

NCE

Apr. 26, 2029

ODE-480

Apr. 26, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Apr 29, 2024	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 100MG

RLD

6 patents2 exclusivities▴

CAPSULE;ORAL | Approved: Apr 26, 2024

Patents (6)

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
10548889	Dec 11, 2038	—	—	Yes	—	—
10610527	Dec 22, 2036	—	—	—		—
10953003	Dec 14, 2036	—	—	Yes	—	—
11045461	Dec 11, 2038	—	—	Yes	—	—
11219621	Dec 22, 2036	—	—	—		—
12115156	Dec 11, 2038	—	—	Yes	—	—

Exclusivities (2)

Code	Date	Status
NCE	Apr 26, 2029	Active
ODE-480	Apr 26, 2031	Active